



Editor's Welcome

Dear colleagues!

In the 19th issue of the International Heart and Vascular Disease Journal, there are the leading article, original and review articles, the expert opinion section and the report on the results of the ESC Congress 2018.

The "Leading article" section includes a work of a group of American scientists dedicated to the treatment of cardiovascular disease in cancer patients with thrombocytopenia. In particular, the pathophysiological aspects of cancer-associated thrombocytopenia and treatment tactics of such patients with coronary heart disease are reviewed.

The "Original articles" section includes two articles. In the first one the author from Egypt studied the safety of ticagrelor administration in post fibrinolysis patients who had myocardial infarction with ST elevation. This study included 200 patients. According to the author's opinion, in patients below 75 years, delayed prescription of ticagrelor 2h after fibrinolysis was not less safe than administration of clopidogrel in terms of thrombolysis-associated bleeding of various severity. The second article was dedicated to detection of clinical and laboratory characteristics of arterial hypertension in patients with chronic kidney disease, stage 5. For this reason, 248 patients on maintenance hemodialysis therapy were involved in this study. It was observed that long-term duration of dialysis is associated with an increase in the number of patients with arterial hypotension. In addition, it was found that 24h-blood pressure monitoring parameters correlated with electrolyte balance impairment and nitrogen metabolism.

The review article of Professor Mekhman N. Mamedov discusses the dynamics of main risk factors and cardiovascular diseases in Europe. It also analyses the organization of cardiologic medical service and the fight against cardiovascular diseases in Russia. The second article made by Russian authors reviews the characteristics of vascular elasticity, approaches to its evaluation and their prognostic meaning. It included data on the possibility of using these parameters for evaluation of cardiovascular risk and therapy control in different categories of patients.

The "Expert opinion" section presents the analytic material prepared by the leading Russian scientists and dedicated to the main positions of the European guidelines on anticoagulant therapy in patients with atrial fibrillation.

Traditionally, our journal reviews the results of clinical studies presented at major scientific events. In this issue we publish the report on the annual Congress of the European Society of Cardiology that was held in Munich (Germany) on August 25-29, 2018.

We invite everybody to collaborate with the journal. We are waiting for your original papers, review articles, discussions, and opinions about problems, treatment and prophylaxis recommendations.

Rafael G. Oganov

Editor-in-Chief

President of the "Cardioprogress" Foundation